Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

850
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
850
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

178
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
178
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

764
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
764

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Addressing challenges in treating rare tumours: the strategy of China's National Cancer Center.

Nature reviews. Drug discovery·2026
Same author

Surveillance and analysis of adverse events following immunization (AEFI) with measles, mumps, and rubella (MMR) vaccine in Zhejiang Province, China, 2020-2025.

Frontiers in public health·2026
Same author

Immunogenicity and safety of co-administered <i>Escherichia coli</i>-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine.

Frontiers in immunology·2026
Same author

Population waning trajectories of vaccine-induced tetanus immunity in Zhejiang, China.

Frontiers in immunology·2026
Same author

Accuracy of Two Novel Self-Contained Darkroom Refractive Screeners Compared with Cycloplegic Retinoscopy and a Traditional Autorefractor in Schoolchildren.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Factors associated with serious adverse event following immunization: a real-world analysis of the vaccine adverse event reporting system 2025.

Frontiers in public health·2026

相关实验视频

Updated: Sep 15, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

对孤儿药物开发的支持系统的洞察:一项比较研究

Ye Leng1, Yu Tang2, Weijie Yu2

  • 1School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.

Therapeutic innovation & regulatory science
|July 14, 2025
PubMed
概括

开发用于罕见疾病的孤儿药物需要协调的支持系统. 这项研究提出了一个框架,并发现美国,欧盟和中国具有基本条件,中国需要在激励和基础设施方面进行改进.

关键词:
临床研究是临床研究.这是一项比较性研究.孤儿药物是一个孤儿药物.罕见疾病是一种罕见的疾病.支持系统支持系统.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

相关实验视频

Last Updated: Sep 15, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

科学领域:

  • 卫生政策和孤儿药物开发
  • 罕见疾病研究和监管科学 罕见疾病研究和监管科学

背景情况:

  • 孤儿药物开发解决了罕见疾病 (RDs) 的重大未满足的医疗需求.
  • 一个协调的支持系统对于推动全球孤儿药物开发至关重要.

研究的目的:

  • 提出一个框架和影响孤儿药物开发的支持系统的尺寸.
  • 评估美国,欧盟和中国的孤儿药物开发条件的现状.
  • 为加强全球孤儿药物开发倡议提出行动计划.

主要方法:

  • 制定支持系统框架,包括法律,技术,动机和后勤因素.
  • 基于框架,对美国,欧盟和中国的孤儿药物开发条件进行比较分析.
  • 制定战略行动计划,以改善孤儿药物开发.

主要成果:

  • 美国,欧盟和中国已经为孤儿药物开发建立了基础条件.
  • 与美国和欧盟相比,中国在经济激励和基本基础设施方面表现出不足.
  • 中国需要改进的具体领域包括定价,报销和现实世界数据 (RWD) 集成.

结论:

  • 一个全面的框架对于评估和加强孤儿药物开发支持系统至关重要.
  • 需要有针对性的改进,特别是在中国,以满足罕见病患者的需求.
  • 该研究为推进全球孤儿药物开发的国家和全球战略提供了一个参考.